Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.64 (
MPP
)
1,876
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Oxidative stress and down-regulated trophic factors are involved in the pathogenesis of nigrostriatal dopamine(DA)rgic neurodegeneration in Parkinson's disease.
Fibroblast growth factor 9
(
FGF9
) is a survival factor for various cell types; however, the effect of
FGF9
on DA neurons has not been studied. The antioxidant melatonin protects DA neurons against neurotoxicity. We used
MPP
(+) to induce neuron death in vivo and in vitro and investigated the involvement of
FGF9
in
MPP
(+) intoxication and melatonin protection. We found that
MPP
(+) in a dose- and time-dependent manner inhibited
FGF9
mRNA and protein expression, and caused death in primary cortical neurons. Treating neurons in the substantia nigra and mesencephalic cell cultures with
FGF9
protein inhibited the
MPP
(+)-induced cell death of DA neurons. Melatonin co-treatment attenuated
MPP
(+)-induced
FGF9
down-regulation and DA neuronal apoptosis in vivo and in vitro. Co-treating DA neurons with melatonin and
FGF9
-neutralizing antibody prevented the protective effect of melatonin. In the absence of
MPP
(+), the treatment of
FGF9
-neutralizing antibody-induced DA neuronal apoptosis whereas
FGF9
protein reduced it indicating that endogenous
FGF9
is a survival factor for DA neurons. We conclude that
MPP
(+) down-regulates
FGF9
expression to cause DA neuron death and that the prevention of
FGF9
down-regulation is involved in melatonin-provided neuroprotection.
...
PMID:Fibroblast growth factor 9 prevents MPP+-induced death of dopaminergic neurons and is involved in melatonin neuroprotection in vivo and in vitro. 1947 51